Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
07:00am, Tuesday, 17'th Feb 2026
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / Moder
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
08:50am, Monday, 16'th Feb 2026
MRNA shares jumped 5.3% as investors rotated into large-cap biotech, betting on its expanding pipeline in volatile trade.
Weekend Morning Brew: AI Jitters, Novo--Hims Clash, McDonald's Beat
07:37am, Saturday, 14'th Feb 2026
Weekly Market HighlightsWeekly breadth was slightly negative with 4,703 advancers versus 4,832 decliners, even as 963 stocks gained more than 10% and 1,151 fel
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend
04:53pm, Friday, 13'th Feb 2026
MRNA is showing early signs of a new bull trend after earnings beat expectations, with technical support holding and upside targets forming above key resistance levels.
MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options
04:13pm, Friday, 13'th Feb 2026
Moderna (MRNA) experienced a wild start to 2026, with shares nearly doubling before pulling back 20% from the recent 52-week high. Rick Ducat dives into technical trends to watch and the various suppo
Moderna Challenges FDA After Flu Shot Review Refusal, 26% Covid Drop
02:16pm, Friday, 13'th Feb 2026
Moderna (MRNA) is escalating its standoff with US regulators at a delicate juncture in its post-pandemic reset. On Friday's analyst call, Chief Executive Office
Moderna Inc (MRNA) Q4 2025 Earnings Call Highlights: Strategic Cost Reductions Amidst Financial Challenges
02:01pm, Friday, 13'th Feb 2026
Total Revenue (Q4 2025): $700 million.Total Revenue (Full Year 2025): $1.9 billion.Net Loss (Q4 2025): $800 million.Net Loss (Full Year 2025): $2.8 billion.Los
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
12:47pm, Friday, 13'th Feb 2026
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates
12:40pm, Friday, 13'th Feb 2026
MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and reaffirming 2026 outlook.
CPI Increased in Line With Expectations
12:21pm, Friday, 13'th Feb 2026
As far as economic reports go, the good news just keeps on coming. Seemingly running on a separate track from investor fears about AI's future role in the economy, today's latest inflation read came i
Moderna shares pop on strong guidance, smaller-than-expected loss
12:07pm, Friday, 13'th Feb 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11% on Friday. The company posted a net loss of $2.11 per
Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms
10:59am, Friday, 13'th Feb 2026
Moderna Inc. (NASDAQ: MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago.
Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates
09:20am, Friday, 13'th Feb 2026
Moderna (MRNA) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.6. This compares to a loss of $2.5 per share a year ago.
Moderna Pops On Fourth-Quarter Report, But Can It Overcome Recent FDA Setbacks?
09:10am, Friday, 13'th Feb 2026
Moderna stock popped Friday after the company reported better-than-expected fourth-quarter sales and reiterated its 2026 outlook.
Moderna Just Crushed Estimates While Everyone Was Looking the Other Way
08:20am, Friday, 13'th Feb 2026
Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street's muted expectations, delivering revenue of $678 million against estimates of $663 million and a loss of $2.
